NTRA Natera, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1604821 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY37.4%
TTM net income YoY46.7%
TTM EPS YoY51.1%
Revenue 3-yr CAGR43.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-9.0%
Net margin-5.7%
FCF margin1.8%
EBITDA margin-7.1%
Returns
ROE-10.6%
ROA-7.2%
ROIC (approx.)-41.9%
Asset turnover1.27x
Leverage & solvency
Liabilities / assets32.0%
Debt / equity0.00x
Current ratio2.81x
Interest coverage-70.84x
Cash quality & payout
Operating cash flow / net income-1.29x
Accruals ratio-16.5%
Payout ratio—
Capex / revenue5.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $793.98M | $752.75M | $696.64M | $665.50M | $592.18M | $546.60M | $501.83M | $476.06M |
| R&D expense | $242.43M | $228.07M | $210.70M | $175.19M | $173.41M | $146.43M | $129.08M | $129.46M |
| SG&A expense | $333.66M | $327.20M | $327.94M | $291.30M | $308.55M | $310.55M | $266.86M | $234.92M |
| Operating income | -$68.32M | -$75.79M | -$93.52M | -$22.79M | -$97.58M | -$110.37M | -$79.18M | -$64.74M |
| Interest expense | $903,000 | $890,000 | $892,000 | $991,000 | $1.04M | $1.03M | $1.00M | $1.29M |
| Pretax income | -$59.61M | -$67.23M | -$84.81M | -$13.33M | -$87.34M | -$100.66M | -$66.76M | -$55.13M |
| Income tax | $299,000 | -$261,000 | $283,000 | -$60.58M | $207,000 | $275,000 | $173,000 | -$1.35M |
| Net income | -$59.91M | -$66.97M | -$85.09M | $47.26M | -$87.54M | -$100.94M | -$66.94M | -$53.77M |
| EBITDA | -$53.62M | -$62.69M | -$79.00M | -$10.41M | -$88.28M | -$101.47M | -$69.94M | -$56.95M |
| EPS (basic) | -0.42 | -0.47 | -0.60 | — | -0.64 | -0.74 | -0.50 | — |
| EPS (diluted) | -0.42 | -0.47 | -0.60 | — | -0.64 | -0.74 | -0.50 | — |
| Weighted avg. shares (diluted) | 144.07M | 143.28M | 141.50M | — | 137.19M | 136.39M | 134.75M | — |
| Banking | ||||||||
| Provision for credit losses | $295,000 | $1.35M | -$222,000 | — | -$626,000 | -$411,000 | -$195,000 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.10B | $1.09B | $1.09B | $1.08B | $1.04B | $1.00B | $973.77M | $945.59M |
| Short-term investments | — | — | — | — | $1.00M | $15.97M | $17.83M | $22.69M |
| Receivables | $471.35M | $421.97M | $417.60M | $296.53M | $286.38M | $309.22M | $318.23M | $314.17M |
| Inventory | $91.70M | $80.35M | $70.72M | $68.44M | $64.64M | $54.27M | $50.37M | $44.74M |
| Current assets | $1.72B | $1.66B | $1.65B | $1.50B | $1.45B | $1.43B | $1.42B | $1.38B |
| PP&E, net | $353.95M | $317.57M | $269.38M | $241.18M | $206.50M | $189.22M | $180.45M | $162.05M |
| Goodwill | $141.10M | $141.10M | $140.86M | $141.07M | — | — | — | — |
| Intangibles | $353.04M | $360.20M | $367.36M | $373.71M | — | — | — | $10.93M |
| Total assets | $2.75B | $2.66B | $2.61B | $2.40B | $1.82B | $1.76B | $1.73B | $1.66B |
| Current liabilities | $612.90M | $553.20M | $558.26M | $441.23M | $442.02M | $384.84M | $365.68M | $344.05M |
| Short-term debt | $80.30M | $80.29M | $80.31M | $80.32M | $80.34M | $80.34M | $80.34M | $80.36M |
| Total liabilities | $878.86M | $836.00M | $840.38M | $685.93M | $569.29M | $510.88M | $492.69M | $465.31M |
| Shareholders' equity | $1.87B | $1.82B | $1.77B | $1.71B | $1.25B | $1.25B | $1.24B | $1.20B |
| Shares outstanding | 144.34M | 143.61M | 142.73M | 139.69M | 137.53M | 136.76M | 135.93M | 132.65M |
| Cash flow statement | ||||||||
| Operating cash flow | $43.93M | $54.79M | $40.17M | $73.89M | $59.39M | $37.57M | $44.45M | $52.89M |
| Capital expenditure | $38.68M | $63.43M | $22.14M | $36.07M | $22.41M | $25.90M | $21.82M | $18.12M |
| Free cash flow | $5.25M | -$8.64M | $18.03M | $37.82M | $36.98M | $11.68M | $22.64M | $34.77M |
| Investing cash flow | -$38.92M | -$63.43M | -$32.14M | -$71.59M | -$19.91M | -$23.90M | -$16.82M | -$11.12M |
| Financing cash flow | $684,000 | $12.21M | $3.76M | $32.41M | $1.94M | $12.58M | $544,000 | $10.97M |
| Depreciation & amortization | $14.70M | $13.10M | $14.52M | $12.38M | $9.30M | $8.90M | $9.24M | $7.79M |
| Stock-based compensation | $106.11M | $103.10M | $95.11M | $92.58M | $90.64M | $93.36M | $77.83M | $71.93M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.